Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

In what order will AI solve the three big problems in drug development? Ben Liu, co-founder of Formation Bio: "There are actually three consequential predictions: drug design and discovery, tox prediction, and clinical efficacy. We believe they will all one day happen, but the winners will be disproportionately right... about the order." "The framework is: where are the benchmarks the cleanest, the data variability the lowest, and the feedback loops the shortest." "Drug discovery gets solved first... we know what a drug binding another drug looks like. The feedback loops are in minutes or days. Historically very low variability because it's physics, it's chemistry." "Tox is a little more complicated, but I know what a liver tox signal looks like. The rodents used are genetically identical. And tox studies are weeks, not years." "Clinical efficacy is gonna take the longest, the feedback loops are the longest, the data is the most highly variable, and you actually don't have really clean benchmarks for most diseases of what getting better looks like."show more

MTS

199,350 subscribers

17,344 views • 2 months ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

.President Donald J. Trump’s Most Favored Nation drug pricing is delivering the lowest pharmaceutical prices in the world and reshoring production to the U.S. “The companies are investing hundreds of billions of dollars.” “We’re going to be the pharmaceutical center of the world within three years.” “Every new drug that they produce, we will get the lowest prices in the developed world.” “For most of the big, the most popular drugs…that are already existing we get the lowest prices in the world.”

.President Donald J. Trump’s Most Favored Nation drug pricing is delivering the lowest pharmaceutical prices in the world and reshoring production to the U.S. “The companies are investing hundreds of billions of dollars.” “We’re going to be the pharmaceutical center of the world within three years.” “Every new drug that they produce, we will get the lowest prices in the developed world.” “For most of the big, the most popular drugs…that are already existing we get the lowest prices in the world.”

HHS Rapid Response

30,862 views • 4 months ago

What it solves QC will power the next frontier of problem solving across all industries; including finance, health sciences, drug and material discovery and AI. All computing as we know it is about to be flipped. Problems which are unsolvable today, will be. QC will solve problems we don't even know we have yet.

What it solves QC will power the next frontier of problem solving across all industries; including finance, health sciences, drug and material discovery and AI. All computing as we know it is about to be flipped. Problems which are unsolvable today, will be. QC will solve problems we don't even know we have yet.

Charles Edwards

77,415 views • 1 year ago

We asked Tweets from Zach Weinberg if it's a good idea to re-shore U.S. drug manufacturing. "It's really stupid. All the strategic stuff is in drug discovery and development." "Drug manufacturing is not something that needs to be done in America." We recommend watching the full video if you are interested in healthcare, pharmaceutical science and economics.

We asked Tweets from Zach Weinberg if it's a good idea to re-shore U.S. drug manufacturing. "It's really stupid. All the strategic stuff is in drug discovery and development." "Drug manufacturing is not something that needs to be done in America." We recommend watching the full video if you are interested in healthcare, pharmaceutical science and economics.

TBPN

17,565 views • 1 year ago

Dr. Ruxandra Teslo argues America's biotech problem isn't the science, it's how slowly we learn from humans: "This is going to be more and more of a bottleneck as science advances especially in oncology. It's not just that we don't have enough clinical trials and they are expensive. This has become worse and worse throughout the years." "The article is particularly focused on these phase one clinical trials. These are the trials where you first take a new drug into humans for the first time. The reason we're focusing on those, they are some of the most important trials because that's where you can actually start to learn and do iterative loops of learning in humans." "What you learn from that goes back into the science and you can engineer something better. We can see from China, they're very very good doing their phase one trials fast, that is very much responsible for propelling them ahead, almost ahead of the US in just a decade, despite the fact that their science is not as good." "We have a very good model for how to do them faster and better, which is Australia." Ruxandra Teslo 🧬 Adam Kroetsch IFP

Dr. Ruxandra Teslo argues America's biotech problem isn't the science, it's how slowly we learn from humans: "This is going to be more and more of a bottleneck as science advances especially in oncology. It's not just that we don't have enough clinical trials and they are expensive. This has become worse and worse throughout the years." "The article is particularly focused on these phase one clinical trials. These are the trials where you first take a new drug into humans for the first time. The reason we're focusing on those, they are some of the most important trials because that's where you can actually start to learn and do iterative loops of learning in humans." "What you learn from that goes back into the science and you can engineer something better. We can see from China, they're very very good doing their phase one trials fast, that is very much responsible for propelling them ahead, almost ahead of the US in just a decade, despite the fact that their science is not as good." "We have a very good model for how to do them faster and better, which is Australia." Ruxandra Teslo 🧬 Adam Kroetsch IFP

MTS

16,475 views • 11 days ago

Lukas says most looksmaxxers are drug addicts “There does appear to be this pervasive trend with all the looksmaxxing and biohacking stuff" "There are pragmatic reasons why you can do all this. You can take PEDs to help with sports, lose weight, live longer, and all these things" "But the majority of people willing to buy peptides from China are usually just drug addicts. So you end up getting bad feedback from internet communities" "The things they are doing and the thoughts they are having about these substances are frequently justifications for drug use rather than actual analysis of the data”

Lukas says most looksmaxxers are drug addicts “There does appear to be this pervasive trend with all the looksmaxxing and biohacking stuff" "There are pragmatic reasons why you can do all this. You can take PEDs to help with sports, lose weight, live longer, and all these things" "But the majority of people willing to buy peptides from China are usually just drug addicts. So you end up getting bad feedback from internet communities" "The things they are doing and the thoughts they are having about these substances are frequently justifications for drug use rather than actual analysis of the data”

dank

20,432 views • 4 months ago

PillPack founder TJ Parker⚡️ says Hims' Wegovy pill alternative is a “$50 drug that doesn't work” and a “financial Hail Mary.” "The Wegovy pill has a specific technology called 'SNAC' to allow you to absorb the peptide and have the drug be effective. Hims explicitly said they didn't use that technology and said they're using liposomal absorption, which maybe works, maybe doesn't, but there's certainly no proof that it works." "There are zero studies and zero approval. This is where it's super different from the injectables, where they weren't changing the formulation. It was very similar to the branded drug." "[The pill] is different in the sense that, here, there's no evidence this drug works at all. So the most likely scenario is they're selling a $50 drug that doesn't work that still has a bunch of side effects because it still has the drug that doesn't get absorbed through your G.I." "It's not an IP issue, it's really an efficacy and safety issue."

PillPack founder TJ Parker⚡️ says Hims' Wegovy pill alternative is a “$50 drug that doesn't work” and a “financial Hail Mary.” "The Wegovy pill has a specific technology called 'SNAC' to allow you to absorb the peptide and have the drug be effective. Hims explicitly said they didn't use that technology and said they're using liposomal absorption, which maybe works, maybe doesn't, but there's certainly no proof that it works." "There are zero studies and zero approval. This is where it's super different from the injectables, where they weren't changing the formulation. It was very similar to the branded drug." "[The pill] is different in the sense that, here, there's no evidence this drug works at all. So the most likely scenario is they're selling a $50 drug that doesn't work that still has a bunch of side effects because it still has the drug that doesn't get absorbed through your G.I." "It's not an IP issue, it's really an efficacy and safety issue."

TBPN

77,039 views • 7 months ago

This is what addiction looks like in Philly. This is what the Philadelphia Police Department and FBI are desperately trying to prevent tragedies such as this- because there are essentially zero prosecutions for drug crimes/user. And this is the result. Secure treatment is a must *not my video*

This is what addiction looks like in Philly. This is what the Philadelphia Police Department and FBI are desperately trying to prevent tragedies such as this- because there are essentially zero prosecutions for drug crimes/user. And this is the result. Secure treatment is a must not my video

StinkyFeat

10,801 views • 10 months ago

$ABCL CEO Carl Hansen explains the net negative overall value creation in biotech and how AbCellera plans to beat it: “I really think it can be beat because there’s a lot of mistakes that get made in where you allocate capital.” “If you’re a biotech and you start a company on a drug, and you go public and have a drug, and now the data is looking not that great, you just keep running that drug. … Because if you quit that drug, the company is done.” “So, because you’re so concentrated on one thing, you end up having blinders. It’s like a cult of a molecule. And even a real, practical, capital access problem that makes you continue to move things forward” ______________________________________ “Another problem is that many of the drugs that get started, get started by people who don’t understand the competitive or commercial landscape and have no intent of ever actually manufacturing it. … Because they know someone else is going to buy it. So then their framework is not ‘Am I making a drug that’s going to make a difference for people?’ The framework is ‘Can I make something that I think someone will take off my hands?’ And that happens a lot.” “There are many acquisitions where a big pharma company spends $10B, $20B, and it’s a complete bust. So really no value is generated for patients but someone was able to get a good exit on that because they anticipated what someone would want. And a lot of decision making gets done like that”. _______________________________________ “I’m not saying that we have this all solved. But what we’re trying to do is create a framework where we are able to take many bets so that we don’t fall in love with anything, or we don’t have to fall in love with anything. … And then always hold up very explicitly what we know and what we don’t know along the dimensions that matter. The dimensions that matter are - Will it work? That’s a science. - When it gets where will people care? - Is it differentiated? - Does it solve a big problem? In order to get it there, is there a path with our resources and expertise that would allow us to see it through?” “When you start to hold things up like that, you start to see where the mistakes are, where the uncertainties are, and you can be more rational in deciding ‘We’re going to run it to here because we get to flip the card and if the card goes the wrong way we’re going to kill it because we’ve got something else behind it.’” “I do think that if done right, and if you can pick the right opportunities, the success rate can be well higher than an order of magnitude better. … And there are examples of this… companies I’ve mentioned, you know, Regeneron, their success rate is at least 10x the industry in bringing programs forward and getting them approved. … So it’s… you can do it better that way”

$ABCL CEO Carl Hansen explains the net negative overall value creation in biotech and how AbCellera plans to beat it: “I really think it can be beat because there’s a lot of mistakes that get made in where you allocate capital.” “If you’re a biotech and you start a company on a drug, and you go public and have a drug, and now the data is looking not that great, you just keep running that drug. … Because if you quit that drug, the company is done.” “So, because you’re so concentrated on one thing, you end up having blinders. It’s like a cult of a molecule. And even a real, practical, capital access problem that makes you continue to move things forward” “Another problem is that many of the drugs that get started, get started by people who don’t understand the competitive or commercial landscape and have no intent of ever actually manufacturing it. … Because they know someone else is going to buy it. So then their framework is not ‘Am I making a drug that’s going to make a difference for people?’ The framework is ‘Can I make something that I think someone will take off my hands?’ And that happens a lot.” “There are many acquisitions where a big pharma company spends $10B, $20B, and it’s a complete bust. So really no value is generated for patients but someone was able to get a good exit on that because they anticipated what someone would want. And a lot of decision making gets done like that”. _ “I’m not saying that we have this all solved. But what we’re trying to do is create a framework where we are able to take many bets so that we don’t fall in love with anything, or we don’t have to fall in love with anything. … And then always hold up very explicitly what we know and what we don’t know along the dimensions that matter. The dimensions that matter are - Will it work? That’s a science. - When it gets where will people care? - Is it differentiated? - Does it solve a big problem? In order to get it there, is there a path with our resources and expertise that would allow us to see it through?” “When you start to hold things up like that, you start to see where the mistakes are, where the uncertainties are, and you can be more rational in deciding ‘We’re going to run it to here because we get to flip the card and if the card goes the wrong way we’re going to kill it because we’ve got something else behind it.’” “I do think that if done right, and if you can pick the right opportunities, the success rate can be well higher than an order of magnitude better. … And there are examples of this… companies I’ve mentioned, you know, Regeneron, their success rate is at least 10x the industry in bringing programs forward and getting them approved. … So it’s… you can do it better that way”

Jack Prescott

31,665 views • 1 month ago

Alex on why AI drug discovery companies need to generate novel data to succeed: "AI models based on the research that's available is a lot of garbage in and garbage out." "A lot of the recorded literature is actually incorrect. There's been tons of studies that show if you go try to replicate the experiments that are in the literature, you don't even get the same results." "The AI companies that I believe are gonna be most set up for success are the companies with a novel way to generate science tokens that don't exist in the public domain."

Alex on why AI drug discovery companies need to generate novel data to succeed: "AI models based on the research that's available is a lot of garbage in and garbage out." "A lot of the recorded literature is actually incorrect. There's been tons of studies that show if you go try to replicate the experiments that are in the literature, you don't even get the same results." "The AI companies that I believe are gonna be most set up for success are the companies with a novel way to generate science tokens that don't exist in the public domain."

Patrick OShaughnessy

126,646 views • 4 months ago

VR founder Jaron Lanier says a future where people are paid for the data they give AI is better than one where everyone depends on billionaires to survive "artificial intelligence is a marketing term, even a religion" The software behind drug discovery and chatbots is very different, but we call it all "AI" because it serves politics, ideology

VR founder Jaron Lanier says a future where people are paid for the data they give AI is better than one where everyone depends on billionaires to survive "artificial intelligence is a marketing term, even a religion" The software behind drug discovery and chatbots is very different, but we call it all "AI" because it serves politics, ideology

Haider.

64,901 views • 4 months ago

I am currently fundraising to build the pharma company of the future. Please email me at [email protected] if you are interested (angel checks + VC welcome). Advances in AI + robotics now enable a ‘single’ human operator to carry out the entire scientific discovery process for a new drug, while costing orders of magnitude less than usual. As proof, I developed two new drugs by myself, with zero outside investment, and assistance only from frontier AI models and liquid-handling robotics. PAC-832 is the world’s first selective GalR1 antagonist for Alzheimer’s disease. PAC-3310 is a new selective M4 agonist for schizophrenia, improving on the selectivity profile of the breakthrough drug Cobenfry (which spearheaded the $14B acquisition of its developer Karuna Therapeutics). This level of efficiency is unprecedented and will enable me to generate >40x more clinical-stage drugs (per dollar spent) than a typical pharma company. Pfizer currently has the most clinical-stage drugs at 137. I will be able to reach 10 clinical-stage drugs within 2 years, then surpass Pfizer within the next 5 years. This plan is contingent on me optimizing one more set of studies known as ‘IND-enabling studies,’ which are required by international regulations to be done prior to clinical trials. This involves me (1) building out my own GMP drug manufacturing facility in SF, and (2) optimizing GLP toxicity studies, which I will be doing in China for cost reasons. Both these things are critical to keep overall costs low and require significant resources, which is why I need to raise money, but are eminently doable. I expect them to take 1-2 years in total. After that, my optimized drug synthesis-to-clinical testing pipeline will be done, and I will start turning the flywheel. The long-term, hardest, yet most important task will be optimizing the clinical trials themselves. In short, I intend to accomplish this by launching the most comprehensive, worldwide site search campaign that I can muster. Once the clinical trials are optimized, then I can finally close the loop on the make -> test -> iterate cycle whose speed dictates progress in drug discovery. The 1950-60s are commonly referred to as the ‘golden age of drug discovery’ due to the large number of transformative medicines that emerged from that era. The key to their success was their tight clinical feedback loop - new drugs were synthesized and rapidly tested in the clinic within 1 year. Today, this process takes 10x as long. Enabled by new technologies like AI and robotics, I strongly believe it is possible to bring back the old level of speed and efficiency. A new golden age of drug discovery is on the horizon, and Pace Pharmaceuticals is its herald.

Douglas Yao

180,635 views • 6 days ago

SITUATION EXPLAINED: What comes after GLP-1s as the next human enhancement drug? We asked Max Marchione, founder of Superpower "GLP-1s, when developed to treat diabetes and obesity, are largely used to make people look better, to maybe increase energy levels. They're used for human enhancement." "I think the next big human enhancement drug is going to be something that allows you to sleep less but feel the same and live the same." "Eli Lilly has actually made a bet on this. They acquired a small molecule that targets narcolepsy... the reason they're paying $6 billion for this is not because it's a narcolepsy drug. It's because they think this same drug could allow normal people, average people, everyone to sleep four hours a night, five hours a night, and feel like they've slept eight." "This drug is an orexin agonist... higher orexin levels are what we see in people who have the short sleeper phenotype."

SITUATION EXPLAINED: What comes after GLP-1s as the next human enhancement drug? We asked Max Marchione, founder of Superpower "GLP-1s, when developed to treat diabetes and obesity, are largely used to make people look better, to maybe increase energy levels. They're used for human enhancement." "I think the next big human enhancement drug is going to be something that allows you to sleep less but feel the same and live the same." "Eli Lilly has actually made a bet on this. They acquired a small molecule that targets narcolepsy... the reason they're paying $6 billion for this is not because it's a narcolepsy drug. It's because they think this same drug could allow normal people, average people, everyone to sleep four hours a night, five hours a night, and feel like they've slept eight." "This drug is an orexin agonist... higher orexin levels are what we see in people who have the short sleeper phenotype."

MTS

236,485 views • 2 months ago

This is what peak inversionism looks like from the current governor of NY, Kathy Hochul. Will you be one of her apostles and go out and spread the good word of the COVID vaccine? So disgusting... Just a few days ago she came out with new guidance for the new strain of COVID. Guess what they are? More boosters, Paxlovid (toxic pfizer drug), and N95 masks.

This is what peak inversionism looks like from the current governor of NY, Kathy Hochul. Will you be one of her apostles and go out and spread the good word of the COVID vaccine? So disgusting... Just a few days ago she came out with new guidance for the new strain of COVID. Guess what they are? More boosters, Paxlovid (toxic pfizer drug), and N95 masks.

Inversionism

33,440 views • 3 years ago

A house is on the market in Bakersfield, California for $155,000 that looks like it’s minutes from collapsing The inside roof looks like it’s starting to cave in Bakersfield is one of the highest areas of drug trafficking in California and home prices are still this outrageous

A house is on the market in Bakersfield, California for $155,000 that looks like it’s minutes from collapsing The inside roof looks like it’s starting to cave in Bakersfield is one of the highest areas of drug trafficking in California and home prices are still this outrageous

Wall Street Apes

72,104 views • 5 months ago

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

“In five years, doing drug design without AI will be like doing science without maths.” Max Jaderberg says the next frontier in drug discovery is collaboration with AI agents. You guide them. They search molecular space and return in hours with what would've taken humans weeks.

vitrupo

157,146 views • 1 year ago

We are in the middle of reshaping of the world order that will hopefully lead to the formation of a stable and fair multipolar world — FM Lavrov ‘Right now, this restructuring looks more like disruption. The fight for power across the world is fierce’

We are in the middle of reshaping of the world order that will hopefully lead to the formation of a stable and fair multipolar world — FM Lavrov ‘Right now, this restructuring looks more like disruption. The fight for power across the world is fierce’

RT

325,503 views • 5 months ago